Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTADIOL versus FEMHRT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTADIOL versus FEMHRT.
DEPO-TESTADIOL vs FEMHRT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone cypionate binds to androgen receptors, modulating gene transcription and promoting male secondary sexual characteristics. Estradiol cypionate binds to estrogen receptors, regulating female reproductive function and bone metabolism.
FEMHRT is a combination of ethinyl estradiol and norethindrone acetate. Ethinyl estradiol is an estrogen that binds to estrogen receptors, promoting proliferation of the endometrium and other estrogen-responsive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, causing secretory changes in the endometrium and inhibiting gonadotropin release from the pituitary, thereby suppressing ovulation.
1 mL (50 mg testosterone enanthate / 2 mg estradiol valerate) intramuscularly every 4 weeks.
One tablet (estradiol 1 mg/norethindrone acetate 0.5 mg) orally once daily
None Documented
None Documented
Testosterone cypionate: approximately 8 days after intramuscular injection due to slow release from oil depot; estradiol cypionate: approximately 5-7 days. Clinically, steady-state concentrations require 4-6 weeks of every-4-week dosing.
Estradiol: terminal half-life approximately 24 hours due to enterohepatic recirculation. Norethindrone: terminal half-life approximately 8-11 hours.
Renal: 90% (metabolites, primarily glucuronide and sulfate conjugates of testosterone and estradiol); Fecal: <10% (biliary excretion of conjugates, minimal enterohepatic recirculation); Unchanged drug: negligible.
Estradiol: primarily renal (60-80% as conjugates, primarily glucuronides and sulfates), fecal (10-20%). Norethindrone: primarily renal (60-70% as metabolites), fecal (30-40%).
Category C
Category C
Hormone Replacement Therapy
Hormone Replacement Therapy